Oxurion NV (LTS:0G99) EBITDA Margin %: -330.27% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0G99 Oxurion NV LTS:0G99
9 GF Score
Price €0.27
GF Value €0.91
! 7 Warning Signs
View Full Analysis

What is Oxurion NV EBITDA Margin %?

Oxurion NV LTS:0G99 9 EBITDA Margin % is -330.27% as of Dec. 2025. GuruFocus rates LTS:0G99 with a GF Score™ of 9/100 and a GF Value™ of €0.91. The stock has 7 warning signs investors should review. Among 939 Biotechnology companies, Oxurion NV ranks worse than 74.76% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Oxurion NV's EBITDA for the six months ended in Dec. 2025 was €-1.83 Mil. Oxurion NV's Revenue for the six months ended in Dec. 2025 was €0.56 Mil. Therefore, Oxurion NV's EBITDA margin for the quarter that ended in Dec. 2025 was -330.27%.

Oxurion NV  (LTS:0G99) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Oxurion NV EBITDA Margin % Related Terms

Oxurion NV EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Oxurion NV's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oxurion NV EBITDA Margin % Chart

Oxurion NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2,461.17 -5,094.45 -7,053.99 9,266.67 -652.43

Oxurion NV Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14,128.92 -111,550.00 250,900.00 0.00 -330.27

LTS:0G99 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, Oxurion NV's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oxurion NV EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oxurion NV's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Oxurion NV's EBITDA Margin % falls into.


LTS:0G99
9GF Score
Oxurion NV LTS:0G99
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oxurion NV EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Oxurion NV's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-3.621/0.555
=-652.43 %

Oxurion NV's EBITDA Margin % for the quarter that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-1.833/0.555
=-330.27 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -330.27% mean?
Oxurion NV (LTS:0G99) has a EBITDA Margin % of -330.27% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Oxurion NV and its competitors. According to the industry distribution chart, Oxurion NV ranks #702 out of 939 companies in the Biotechnology industry, placing it in the top 74.8%.
Is Oxurion NV's EBITDA Margin % too high?
Oxurion NV's current EBITDA Margin % is -330.27%. Based on the distribution chart, Oxurion NV ranks #702 out of 939 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Oxurion NV has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Oxurion NV's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oxurion NV ranks #702 out of 939 companies for EBITDA Margin %. This places Oxurion NV in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Oxurion NV and its competitors. Oxurion NV's current EBITDA Margin % is -330.27%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxurion NV stock overvalued right now?
Oxurion NV (LTS:0G99) has a current EBITDA Margin % of -330.27%. The stock's GF Value™ is €0.91, compared to a current price of €0.27 — trading 70% below its estimated fair value. The current EBITDA Margin % is -330.27%. Oxurion NV's overall GF Score™ is 9/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Oxurion NV (LTS:0G99), the current EBITDA Margin % is -330.27% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oxurion NV (LTS:0G99) Overvalued in 2026?

Based on GuruFocus' analysis, Oxurion NV stock appears to be undervalued. The current stock price of €0.27 is trading 70% below its estimated GF Value™ of €0.91.

Key valuation signals for LTS:0G99:

  • EBITDA Margin %: -330.27%
  • GF Value™: €0.91 vs. price of €0.27 (70% below fair value)
  • GF Score™: 9/100 with 7 warning signs

No single metric tells the full story. See the LTS:0G99 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oxurion NV Business Description

Other Exchanges TG40:GermanyOXUR:Belgium
Address Gaston Geenslaan 1, Leuven, BEL, B-3001
Oxurion NV is a holding company specializing in acquiring and integrating clinical research services companies (CROs) covering the full clinical research value chain across Europe.
9GF Score

Get the complete analysis for LTS:0G99

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.27
Price
€0.91
GF Value